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A B S T R A C T
Objective: To investigate the relationship between length of hospitalisation (LOH) and post-discharge outcomes
in acute heart failure (AHF) patients and to ascertain whether there are different patterns according to de-
partment of initial hospitalisation.
Methods: Consecutive AHF patients hospitalised in 41 Spanish centres were grouped based on the LOH (< 6/6-
10/11-15/> 15 days). Outcomes were defined as 90-day post-discharge all-cause mortality, AHF readmissions,
and the combination of both. Hazard ratios (HRs), adjusted by chronic conditions and severity of decom-
pensation, were calculated for groups with LOH>6 days vs. LOH<6 days (reference), and stratified by hos-
pitalisation in cardiology, internal medicine, geriatrics, or short-stay units.
Results: We included 8563 patients (mean age: 80 (SD=10) years, 55.5% women), with a median LOH of 7 days
(IQR 4–11): 2934 (34.3%) had a LOH<6 days, 3184 (37.2%) 6–10 days, 1287 (15.0%) 11–15 days, and 1158
(13.5%)> 15 days. The 90-day post-discharge mortality was 11.4%, readmission 32.2%, and combined end-
point 37.4%. Mortality was increased by 36.5% (95%CI= 13.0–64.9) when LOH was 11–15 days, and by 72.0%
(95%CI= 42.6–107.5) when> 15 days. Conversely, no differences were found in readmission risk, and the
combined endpoint only increased 21.6% (95%CI= 8.4–36.4) for LOH>15 days. Stratified analysis by hos-
pitalisation departments rendered similar post-discharge outcomes, with all exhibiting increased mortality for
LOH>15 days and no significant increments in readmission risk.
Conclusions: Short hospitalisations are not associated with worse outcomes. While post-discharge readmissions
are not affected by LOH, mortality risk increases as the LOH lengthens. These findings were similar across
hospitalisation departments.
1. Introduction
Heart failure (HF) is a world-wide pandemic associated with sig-
nificant morbidity, mortality, and cost burden [1,2]. For every health
care system, the majority of HF costs are related to hospitalisations
during acute decompensations and are proportional to the length of
hospitalisation (LOH) required [3]. Therefore, many efforts have been
directed at shortening the LOH of patients with acute HF (AHF).
Moreover, this strategy is potentially beneficial due to a reduction of
the hazards associated with hospitalisation itself, which include ex-
posure to nosocomial infection and complications, iatrogenic harm, or
1 Òscar Miró and Joan Padrosa have equally contributed to this study and
should both be considered as first author.
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the development of delirium in the elderly. Shortening hospitalisation
could also impact the rates of post-hospital syndrome, which occurs in
recently hospitalised patients who are not only recovering from their
acute illness, but also experience a transient period of generalised risk
for a wide range of adverse health events [4]. In this sense, data on
patients with AHF from the VERITAS trials demonstrated that longer
LOH was associated with a higher rate of post-discharge mortality [5].
To meet the objective of limiting the LOH to a minimum, some coun-
tries (e.g., Spain) have promoted the creation of short-term units, the
purpose of which is to provide quick, coordinated management of pa-
tients who have no additional challenges other than decompensation of
a chronic condition, such as AHF [6,7].
Nonetheless, while it has been proposed that shortening LOH in
AHF is the best way to mitigate expenditures and reduce post-discharge
adverse outcome risk [8], it is also feasible that it may worsen short-
term outcomes. Certainly, residual congestion or unsolved residual
organ damage is more likely to be present at hospital discharge in pa-
tients with a very short period of in-hospital supervised management
and treatment. In addition, while well-defined discharge planning and
structured outpatient follow-up improve AHF patient outcomes [9],
very short hospitalisations could interfere with the complete im-
plementation of such measures. To date, the impact of LOH on post-
discharge outcomes has been poorly explored in the real world sce-
nario. Although randomised clinical trials are the gold standard to
unequivocally demonstrate the benefit of new treatment or disease
approaches, inpatient hospital registries remain the primary source of
real-world data as they include unselected patients representing the full
spectrum of HF [10]. Our purpose was to explore the relationship be-
tween the LOH and post-discharge outcomes in a large registry of
consecutive patients admitted to hospital for AHF. Our hypothesis is
that a short duration of hospitalisation does not negatively impact
outcomes in AHF. An exploratory stratified analysis by the main hos-
pitalisation departments of AHF patients was also performed.
2. Methods
2.1. Setting
The LOHRCA (Length Of Hospitalisation and its Relationship with
outComes in Acute heart failure) study was an exploratory, secondary
analysis within the EAHFE (Epidemiology of Acute Heart Failure in
Emergency departments) Registry. This registry was initiated in 2007
and every 2–3 years it carries out a 1–2-month recruitment period of all
consecutive patients diagnosed with AHF in Spanish EDs participating
in the project. To date, 5 recruitment phases (in 2007, 2009, 2011,
2014, and 2016) have been performed with the participation of 41 EDs
from community and university hospitals across Spain (representing
about 13% of the hospitals belonging to the Spanish public healthcare
system), enrolling a total of 13,791 AHF patients. The LOHRCA study
used the 12,843 patients recruited in phases 2 to 5 since data on LOH
was not recorded in phase 1. Details of patient inclusion have been
reported previously [11,12]. Briefly, the principal investigators of each
emergency department participating in the EAHFE Registry attend a
general meeting held before every recruitment phase in order to
homogenize the logistics, protocol definitions, as well as the inclusion
and exclusion criteria. All principal investigators are provided with a
common dictionary of terms in order to have standard definitions at all
centres (available as Supplementary Table 1). The principal in-
vestigators then explain protocol instructions to the emergency physi-
cians of their respective centres during a weekly ED meeting preceding
patient recruitment. During the recruitment time frame, patient enrol-
ment is done by any attending emergency physician in the participating
EDs. These physicians are responsible for the detection of potential
cases of patients with AHF. All suspected cases are confirmed by the
principal investigator of each centre to ensure the patients meet the
diagnostic criteria of AHF based on the Framingham clinical criteria
[13]. If possible, the diagnosis is confirmed by measurement of plasma
natriuretic peptide and/or echocardiography during ED or hospital
stay, following the current recommendations of the ESC guidelines
[14], and this is done in about 92% of cases. The principal investigator
of each centre is responsible for the final diagnostic adjudication of the
cases. The only exclusion criterion of the EAHFE Registry is a con-
current primary diagnosis of ST-elevation myocardial infarction
(STEMI), which occurs in about 3% of AHF cases. The EAHFE Registry
is only observational, does not include any planned intervention, and
the management of patients is entirely based on the attending ED
physician decisions.
2.2. Ethics
The EAHFE Registry protocol was approved by a central Ethics
Committee at the Hospital Universitario Central de Asturias (Oviedo,
Spain) with the reference numbers 49/2010, 69/2011, 166/13, and
160/15. Due to the non-interventional design of the registry, Spanish
legislation allows central Ethical Committee approval, accompanied by
notification to the local Ethical Committees. All participating patients
gave informed consent to be included in the registry and to be con-
tacted for follow-up. The LOHRCA study was carried out in strict
compliance with the Declaration of Helsinki principles.
2.3. Design and variables recorded
All patients hospitalised after an ED diagnosis of AHF and dis-
charged alive, in whom data regarding the LOH and mortality were
available, were eligible for this study. The LOHRCA study was designed
to analyse outcomes in 4 LOH subgroups. Groups were defined from a
previous analysis of outcome prevalence versus time (Fig. 1), and
consisted of LOH ≤5, 6 to 10, 11 to 15, and > 15 days. The LOH was
defined as the calendar day that patients presented to the ED until the
calendar day that they were discharged from the hospital.
In addition to the LOH (classificatory variable), another 22 in-
dependent variables regarding demographic data (2 variables), co-
morbidities (12 variables), baseline status (3 variables) and chronic
treatments for HF (5 variables) were recorded to delineate the chronic
underlying risk profiles that could potentially impact on the primary
endpoints. With respect to the severity of the AHF episode itself, we
estimated the risk of each patient using the previously developed
Fig. 1. Probability of adverse outcomes plotted against day by day of length of
hospitalisation.
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MEESSI score11and EFFECT score [15], which assess the 30-day risk of
death in ED AHF and in hospitalised AHF patients, respectively. For
both, the higher the score, the higher the risk. The initial department to
which the patient was transferred after ED management was considered
responsible for hospitalisation because, although the internal transfer
rate between different departments is< 10% in Spanish hospitals, we
did not record further departments to which a patient was moved when
the initial department was not the same as the final department from
which the patient was discharged home.
2.4. Outcomes
We recorded three main post-discharge outcomes, defined as
starting at the time of discharge from hospitalisation, and included 90-
day all-cause death, 90-day readmission due to AHF, and the combined
endpoint. The 90-day period was selected because it has been proposed
as the vulnerable post-discharge period for patients with AHF [16].
Follow-up was performed by telephone contact and consultation of
medical records.
2.5. Statistical analysis
Continuous variables are expressed as mean and standard deviation
(SD) or median and interquartile range (IQR) if not normally dis-
tributed, and discrete variables as absolute values and percentages.
Comparison among groups was carried out using one-way ANOVA for
continuous variables and the chi square test for discrete variables.
Outcomes among the groups of LOH were compared by means of Cox
Fig. 2. Flow chart for patient inclusion.
LOS: length of stay.
Table 1




















Age (years) (mean (SD)) 80.2 (10.2) 10 (0.1) 80.9 (10) 80.2 (10.2) 80.1 (10.2) 78.7 (10.5) <0.001
Female 4742 (55.5) 24 (0.3) 1664 (56.9) 1786 (56.3) 708 (55.1) 584 (50.6) 0.006
Comorbidities
Hypertension 7215 (84.4) 16 (0.2) 2503 (85.5) 2684 (84.4) 1079 (83.9) 949 (82.2) 0.146
Diabetes mellitus 3665 (42.9) 18 (0.2) 1213 (41.5) 1362 (42.8) 575 (44.7) 515 (44.6) 0.256
Ischaemic heart disease 2467 (28.9) 19 (0.2) 859 (29.3) 894 (28.1) 379 (29.5) 335 (29) 1.396
Heart valve disease 2282 (26.7) 17 (0.2) 789 (26.9) 819 (25.8) 347 (27) 327 (28.3) 0.746
Atrial fibrillation 4235 (49.6) 17 (0.2) 1544 (52.8) 1546 (48.6) 604 (47) 541 (46.9) <0.001
Chronic kidney failure (creatinine>2mg/mL) 2298 (26.9) 16 (0.2) 719 (24.6) 863 (27.1) 382 (29.7) 334 (28.9) 0.002
Cerebrovascular disease 1155 (13.5) 18 (0.2) 413 (14.1) 384 (12.1) 175 (13.6) 183 (15.9) 0.016
Peripheral artery disease 839 (9.8) 19 (0.2) 281 (9.6) 296 (9.3) 136 (10.6) 126 (10.9) 0.648
Chronic obstructive pulmonary disease 2105 (24.6) 23 (0.3) 681 (23.3) 786 (24.7) 336 (26.1) 302 (26.2) 0.228
Dementia 993 (13) 938 (11) 324 (12.3) 389 (13.7) 161 (13.9) 119 (11.9) 0.488
Active neoplasia 1068 (14) 941 (11) 348 (13.3) 398 (14) 162 (14) 160 (16) 0.424
Prior episodes of acute heart failure 5088 (60.5) 148 (1.7) 1784 (61.8) 1850 (59.2) 763 (60.3) 691 (60.9) 0.44
Baseline status
Barthel Index (points) (mean (SD)) 79.16 (24.56) 969 (11.3) 80.55 (23.54) 78.91 (24.58) 78.01 (26.65) 77.47 (25.72) 0.001
NYHA class III-IV 2029 (25.1) 478 (5.6) 622 (22.3) 747 (24.8) 330 (27.5) 330 (30.5) <0.001
Left ventricular ejection fraction (%) (mean (SD)) 50.98 (15.16) 3877 (45.3) 51.11 (15.12) 51.27 (14.96) 50.97 (14.96) 49.93 (15.92) 0.278
Chronic treatments at home
Diuretics (any) 6363 (76) 194 (2.3) 2184 (75.7) 2354 (75.8) 951 (75.7) 874 (77.8) 1.018
Renin-angiotensin system inhibitors 4792 (57.3) 195 (2.3) 1695 (58.7) 1807 (58.2) 695 (55.3) 595 (53) 0.006
Beta-blockers 3416 (40.8) 196 (2.3) 1276 (44.2) 1188 (38.3) 506 (40.3) 446 (39.7) <0.001
Mineralocorticoid-receptor antagonists 1428 (17.1) 193 (2.3) 480 (16.6) 511 (16.5) 209 (16.6) 228 (20.3) 0.046
Digoxin 1295 (15.5) 203 (2.4) 460 (16) 487 (15.7) 177 (14.1) 171 (15.2) 0.928
Severity of current heart failure decompensation
MEESSI score (mean (SD)) −2.69 (1.13) 3526 (41.2) −2.83 (1.09) −2.66 (1.14) −2.58 (1.12) −2.52 (1.16) <0.001
EFFECT score (mean (SD)) 115.7 (25.1) 3865 (45.1) 113.7 (24.6) 116.6 (25.2) 117.1 (25.9) 117.6 (24.8) <0.001
MEESSI score estimates the 30-day mortality risk and includes 13 parameters: age, Barthel index, NYHA class, decompensation associated with acute coronary
syndrome, low output signs and symptoms, systolic blood pressure, respiratory rate, oxygen saturation, potassium, NT-proBNP, troponin, creatinine, and left ven-
tricular hypertrophy in ECG. The higher the score, the higher the risk.
EFFECT score estimates the 30-day mortality risk and includes 10 parameters: age, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, hepatic
cirrhosis, cancer, respiratory rate, systolic blood pressure, urea nitrogen and sodium. The higher the score, the higher the risk.
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regression analysis and expressed as hazard ratios (HRs) with 95%
confidence intervals (95% CI) using the shortest LOH stay group
(< 6 days) as the reference standard. Curves depicting unadjusted
proportional hazards were made. Hazard ratios were adjusted for all
independent variables of chronic status with a p < 0.10 in the uni-
variate analysis, and by decompensation severity determined by the
MEESSI and EFFECT scores. Additional models of adjustment were
created by a combination of the above. Missing values were replaced
using the multiple imputation technique, generating 5 datasets with no
missing values for the variables included in the adjustment. As sensi-
tivity analysis, hospitalisations ≤10 days were analysed in 1-day per-
iods, with LOH of 0–3 days as the reference standard, in order to detect
risks in groups in the shortest LOH. We also planned a stratified analysis
of the three outcomes for the four main admission wards in patients
hospitalised due to AHF: cardiology, internal medicine, geriatrics and
short-stay unit. Statistical significance was accepted if the 95% con-
fidence interval (CI) of the excluded the value 1, or the p value
was<0.05. Since this was an exploratory study, a pre-hoc sample size
calculation was not made.
3. Results
Of the 12,843 patients included in the EAHFE 2 to 5 registries, 9674
were hospitalised and 8563 were discharged alive and had enough data
available to be included in the LOHRCA study (Fig. 2). Overall, the
mean age was 80 (SD 10) years, and 55.5% were women. Comorbidities
were common, with the most frequent being hypertension (84.4%),
atrial fibrillation (49.6%) and diabetes mellitus (42.9%) (Table 1). With
respect to baseline status, the mean Barthel index was 79 (SD 25), left
ventricular ejection fraction 51% (SD 15), and 25.1% were NYHA class
III or IV. A prior episode of AHF was recorded in 60.5% of patients, and
57.3% and 40.8% were receiving chronic treatment with renin-angio-
tensin system inhibitors and beta-blockers, respectively. Table 1 shows
the remaining data regarding baseline and chronic status. With regard
to severity of decompensation, the MEESSI and EFFECT scores
were− 2.69 (SD 1.13), and 116 (SD 25), respectively (Supplementary
Fig. 1).
The median LOH was 7 days (IQR 4–11). The LOH was< 6 days in
2934 patients (34.3%), 6–10 in 3184 (37.2%), 11–15 in 1287 (15.0%),
and > 15 in 1158 (13.5%). These groups were different in 10 out of 22
chronic or baseline status variables (Table 1). They also differed in the
MEESSI and the EFFECT scores, and the higher the severity of the acute
episode (assessed by either score), the longer the LOH (Table 1).
During the 90-day post-discharge period, 975 (11.4%) patients died,
2760 (32.2%) were readmitted, and 3202 (37.4%) achieved the com-
bined endpoint (Fig. 3). With respect to patients with a LOH of< 6
days, unadjusted HRs for mortality showed statistically significant in-
creases of 50.8% and 86.6% if hospitalised 11–15 days and > 15 days,
respectively. Unadjusted HRs for 90-day readmission showed a statis-
tically significant increase of 15.4% for patients with LOH>15 days,
and the 90-day combined endpoint showed statistically significant in-
creases of 9.0%, 12.3% and 31.0% for cohorts with LOH of 6–10,
11–15, and > 15 days, respectively (Fig. 3 and Table 2). The models
with progressive adjustment showed similar results for 90-day mor-
tality, and statistically significant increases were maintained with the
complete adjustment (model 6) for mortality in patients with LOH
11–15 days (36.5% increase vs. LOH<6 days; 95% CI 13.0% to 64.9%)
and > 15 days (72.0% increase vs. LOH<6 days, 95% CI 42.5% to
107.5%). On the other hand, LOH had a neutral effect on 90-day
readmission after complete adjustment (model 6), while patients with
LOH>15 days had significantly higher rates of the combined endpoint
(22% increase vs. LOH<6 days, 95% CI 9% to 37%) (Table 2). The
Fig. 3. Unadjusted curves corresponding to proportional hazards of the four length of hospitalisation groups for the three outcomes evaluated in the present study.
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detailed daily analysis of LOH during the first 10 days showed no dif-
ferences in adjusted HRs for mortality, although there were increases in
the adjusted HR for readmissions and the composite endpoint in pa-
tients with a LOH of 8 and 9 days compared with 0–3 days (Fig. 4).
Stratified analysis was performed according to whether patients had
initially been admitted to cardiology (1911 patients, 22.3%), internal
medicine (4716, 43.4%), geriatrics (620, 7.2%) or a short stay unit
(1408, 16.4%). With few exceptions, similar patterns of HRs were ob-
served in post-discharge outcomes for the four departments (Fig. 5).
Increased mortality was observed in patients hospitalised>15 days,
irrespective of the initial admission department, with increments ran-
ging from 66% (internal medicine) to 216% (geriatrics). Conversely,
there was no increased readmission risk, and only a significant incre-
ment in risk of combined endpoint was observed in patients initially
hospitalised in cardiology or short-stay units for> 15 days (29% and
98%, respectively).
4. Discussion
The results of the LOHRCA study were obtained from a consecutive
cohort with prospective collection of clinical data of patients hospita-
lised for AHF in 41 Spanish hospitals and provide three main findings.
First, short hospitalisations were not associated with an increased risk
of adverse post-discharge outcomes during the subsequent 90 days,
while the risk of presenting an adverse event increased in patients
hospitalised for> 15 days. Second, while mortality increased with a
longer LOH, readmission did not. And third, the department where the
patient had initially been hospitalised did not seem to influence the
previous two findings.
Our results suggest that short hospitalisations are a safe and even a
recommendable option for patients with AHF, since after adjusting for
potential differences in baseline and chronic status as well as for the
severity of decompensation, neither mortality nor readmission in-
creased when the LOH was 10 or less days. After this time point, we
found that mortality progressively increased with a lengthening in the
LOH, with a 73% increase in patients in whom the LOH surpassed
15 days compared to those not surpassing 5 days. This finding is in line
with recent data from a Polish study of 765 patients discharged from 32
cardiology wards. In this study, mortality increased 120% during an
average 414-day follow-up in patients with an index hospitalisation
exceeding 21 days compared to patients hospitalised<7 days [17].
Similarly, Sud et al. reported a 28% increase in 30-day all-cause mor-
tality in 58,230 AHF patients admitted to any hospital ward (not only
cardiology) in Ontario, Canada for 9 days or more compared with those
with a LOH of 5–6 days [18]. Therefore, our data confirm and expand
the direct relationship between LOH and the risk of death reported in
such studies. As we prospectively recorded clinical data (in contrast
with previous studies that were based on administrative data
Table 2
Unadjusted and adjusted hazard ratios (HR) of adverse outcomes per length of hospitalisation group.
< 6 days 6–10 days 11–15 days > 15 days
90-day all-cause mortality
Unadjusted HR 1 (Reference) 1.081 (0.921–1.265) [0.339] 1.508 (1.250–1.820) [<0.001] 1.866 (1.553–2.242) [<0.001]
Adjusted HR (model 1) 1 (Reference) 1.064 (0.906–1.249) [0.447] 1.441 [1.193–1.740) [<0.001] 1.850 (1.536–2.227) [<0.001]
Adjusted HR (model 2) 1 (Reference) 0.996 (0.847–1.171) [0.958] 1.351 (1.118–1.631) [0.002] 1.651 (1.371–1.989) [<0.001]
Adjusted HR (model 3) 1 (Reference) 1.049 (0.893–1.232) [0.562] 1.455 (1.206–1.756) [<0.001] 1.847 (1.537–2.219) [<0.001]
Adjusted HR (model 4) 1 (Reference) 0.986 (0.839–1.158) [0.862] 1.325 (1.097–1.599) [0.003] 1.600 (1.329–1.928) [<0.001]
Adjusted HR (model 5) 1 (Reference) 1.040 (0.885–1.222) [0.635] 1.407 (1.164–1.699) [<0.001] 1.797 (1.490–2.167) [<0.001]
Adjusted HR (model 6) 1 (Reference) 1.009 (0.859–1.186) [0.911] 1.365 (1.130–1.649) [0.001] 1.720 (1.426–2.075) [<0.001]






90-day readmission due to AHF
Unadjusted HR 1 (Reference) 1.070 (0.980–1.167) [0.131] 1.030 (0.915–1.158) [0.628] 1.154 (1.019–1.307) [0.024]
Adjusted HR (model 1) 1 (Reference) 1.057 (0.968–1.154) [0.213] 1.001 (0.889–1.126) [0.992] 1.103 (0.973–1.250) [0.127]
Adjusted HR (model 2) 1 (Reference) 1.052 (0.964–1.148) [0.256] 1.005 (0.893–1.130) [0.939] 1.121 (0.990–1.270) [0.073]
Adjusted HR (model 3) 1 (Reference) 1.063 (0.974–1.160) [0.173] 1.024 (0.910–1.152) [0.696] 1.148 (1.014–1.300) [0.030]
Adjusted HR (model 4) 1 (Reference) 1.052 (0.964–1.149) [0.256] 0.993 (0.883–1.118) [0.911] 1.091 (0.962–1.237) [0.175]
Adjusted HR (model 5) 1 (Reference) 1.050 (0.962–1.147) [0.276] 0.993 (0.889–1.126) [0.997] 1.103 (0.974–1.251) [0.123]
Adjusted HR (model 6) 1 (Reference) 1.046 (0.958–1.142) [0.316] 0.987 (0.877–1.111) [0.830] 1.083 (0.955–1.228) [0.215]







Unadjusted HR 1 (Reference) 1.090 (1.002–1.175) [0.044] 1.123 (1007–1.252) [0.038] 1.310 (1.170–1.467) [<0.001]
Adjusted HR (model 1) 1 (Reference) 1.075 (0.988–1.169) [0.092] 1.087 (0.974–1.213) [0.136] 1.248 (1.113–1.400) [<0.001]
Adjusted HR (model 2) 1 (Reference) 1.064 (0.978–1.156) [0.148] 1.084 (0.972–1.209) [0.149] 1.256 (1.120–1.407) [<0.001]
Adjusted HR (model 3) 1 (Reference) 1.080 (0.993–1.173) [0.072] 1.115 (0.999–1.173) [0.052] 1.301 (1.162–1.457) [<0.001]
Adjusted HR (model 4) 1 (Reference) 1.062 (0.977–1.155) [0.157] 1.069 (0.958–1.193) [0.235] 1.222 (1.090–1.369) [0.001]
Adjusted HR (model 5) 1 (Reference) 1.065 (0.979–1.159) [0.141] 1.077 (0.979–1.202) [0.184] 1.232 (1.099–1.382) [<0.001]
Adjusted HR (model 6) 1 (Reference) 1.058 (0.973–1.151) [0.190] 1.066 (0.955–1.190) [0.256] 1.216 (1.084–1.364) [0.001]






AHF: acute heart failure.
Bold numbers denote comparisons with p values< 0.05.
Model 1: adjusted for differences in chronic status (age and sex; atrial fibrillation, chronic kidney disease and cerebrovascular disease as comorbidities; baseline
Barthel index and NYHA class; and chronic treatment with renin-angiotensin system inhibitors beta-blockers and mineralcorticosteroid-receptor antagonists).
Model 2: adjusted for the MEESSI score.
Model 3: adjusted for the EFFECT score.
Model 4: adjusted for differences in chronic status and the MEESSI score.
Model 5: adjusted for differences in chronic status and the EFFECT score.
Model 6: adjusted for differences in chronic status, the MEESSI and the EFFECT score.
Propensity score matching comparisons were made between 2688, 1257 and 1091 pairs for the comparison between the reference group (< 6 days) and the 6–10,
11–15 and > 15 days groups, respectively.
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collection), we were able to include the severity of decompensation in
the adjustment of our estimations. However, although our results were
very consistent in all the adjusted models we developed, an increase in
mortality with a lengthening of LOH may just signal a more vulnerable
population requiring longer hospitalisation and at higher risk of post-
discharge death rather than demonstrating a direct influence of LOH in
the risk of death.
Conversely, we did not detect an increase in 90-day readmission
rates related to LOH. This finding is in contrast with previous studies
assessing the relationship between LOH and post-discharge readmission
[18–21]. While two American studies have demonstrated that only
longer hospitalisations are related to all-cause and HF-related read-
missions [19,20], the Canadian Sud et al. study reported the same
finding for all-cause readmission but with a U-shape relationship for
HF-related readmission, with patients with both the the shortest and
longest LOH being at increased risk [18]. By contrast, analysis of the
6827 patients from 27 countries included in the ASCEND-HF trial
showed that a longer LOH was associated with a lower risk in read-
mission [21]. Therefore, our findings are remarkably different from
those obtained in these previous studies, as we failed to detect any
relationship between LOH and the risk of post-discharge readmission.
Hypothetically, the fact that we accounted for the severity of the epi-
sode could have contributed to this absence of relationship. Re-
markably, only HF-related readmission was taken into account in the
LOHRCA study. Nonetheless, from all the information currently avail-
able, it seems evident that while the relationship between LOH and
post-discharge mortality is clear and direct, the existence and the way
of the relationship with post-discharge readmission risk is still unclear
and needs further studies.
It is of note that we found a relatively uniform increase in mortality
in long hospitalisations across the most frequent departments and
specialties involved in in-hospital AHF care. While our results are un-
ique in that this approach to investigate the effect on post-discharge
outcomes in individual departments has not previously been performed
by other authors, they are contrary to many findings suggesting that the
management of AHF by cardiologists may have better outcomes
[22–24]. It should be noted that the results of the LOHRCA study
cannot be interpreted as a result of differences in the performance of
these specialities managing AHF patients during admission, but rather
refer to outcomes obtained during the vulnerable phase following pa-
tient discharge. As previously commented, one possible explanation is
that an increased LOH is just a marker of patients with the highest risk,
Fig. 4. Comparative hazard ratios for the fully adjusted model (adjusted for differences in baseline and chronic status, the MEESSI score and the EFFECT score) for
the three outcomes evaluated in the study: 90-day mortality (up), readmission (middle) and combined endpoint (down). Analysis is presented for the four predefined
length of hospitalisation groups (left) and detailed day by day for the first 10 days (right).
Asterisks indicate p < 0.05 respect to reference group (Ref.)
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and does not directly cause the increase in mortality observed. We have
tried to limit this possibility by making multiple adjustments, thereby
minimizing the potential effect of the different chronic or acute patient
profiles, although unknown confounders may persist. It is well known
that for patients experiencing an episode of AHF, the average survival is
2 years, and the most vulnerable period is the 3-month window im-
mediately after discharge [16,25]. Reducing persistent subclinical
congestion, increasing the use of disease-modifying heart failure
therapies, and ensuring optimal transitions of care after hospital dis-
charge have been described as essential steps in improving outcomes
for AHF patients [24]. Nonetheless, our findings suggest that increases
in LOH do not achieve greater or better implementation of these key
steps.
Again, a similar pattern of readmission was found for the four de-
partments, with no increase of readmission risk associated with a longer
LOH. Only the combined endpoint occurred more often in patients in-
itially managed in the cardiology department or in the short-stay units
and who had a LOH>15 days. One limitation which might explain this
finding is that we do not know how frequent discharge plans were
implemented by each department. A recent meta-analysis of 41 ran-
domised trials testing transitional care interventions demonstrated that
implementation of transitional plans at AHF patient discharge achieves
a significant reduction of 8% and 29% in the risk of rehospitalisation
and ED visits, respectively [26]. As shown by our results on mortality, it
Fig. 5. Stratified analysis of the effect of length of hospitalisation on 90-day outcomes according to the department of hospitalisation (fully adjusted model).
Bold numbers in the right columns denote p value< 0.05.
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is clear that a longer LOH with a greater opportunity for intervention
was not successful in changing outcomes. Albeit not statistically sig-
nificant, our finding of a higher increment of readmission (49%) in
patients hospitalised longer than 15 days and who were initially ad-
mitted to short-stay units (on top of the 143% of increase in mortality)
probably contributed to the significant increment (98%) in the com-
bined endpoint in the same group of patients. Many authors have un-
derlined the importance of candidate selection to define which patients
should be admitted to short-stay units, as failure to do this usually leads
to prolonged hospitalisations [7,8,27,28].
Our study has some limitations. First, this is a secondary analysis
limited to hypothesis generation that requires confirmation in future
trials. Second, since there was no sample size calculation due to the
exploratory nature of the study, a type-II error cannot be excluded in
some of the estimations made, especially in the stratified analysis by
departments (due to the small number of events in certain outcomes
and/or departments). Third, in this real-life cohort without interven-
tion, attending physicians followed their usual local protocols and did
not receive any specific instructions about the precise time for hospital
discharge and patient transition. Fourth, the patients were from a single
country with a universal public health care system, and since interna-
tional heterogeneity in organisational and transition processes is high
[29], external validation of our results should be carried out in further
studies in other countries with different healthcare system models. And
fifth, we recorded the department which was responsible for admission
once emergency department care was completed, but we did not track
further patient transfers from the initial department to others. There-
fore, post-discharge outcomes cannot entirely be attributed to the
management of the department to which patients were initially ad-
mitted. An example of this limitation is the short-stay units where,
despite most of the participating hospitals having a LOH limited to 96 h,
some patients initially admitted to these units had a LOH of> 10 (and
even 15) days, probably because they were moved to other departments
for reasons we do not know.
Despite these limitations, we can conclude that short hospitalisa-
tions in AHF patients are not associated with poorer outcomes, and that
for the particular case of all-cause mortality, patients hospitalised
longer than 10 days could be at increased risk. No large differences in
outcomes were observed among the main departments responsible for
the initial hospitalisation.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejim.2019.08.007.
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